Business Context and Reporting Period
This Form 8-K was filed by Amphastar Pharmaceuticals, Inc. on March 8, 2023, reporting a material definitive agreement entered into on the same date. The Company is a Delaware corporation with principal executive offices in Rancho Cucamonga, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to the specific agreement described below.
- Agreement Cost Cap: Approximately $0.5 million (payable in Chinese yuan, adjusted for exchange rates).
- Pricing Structure: Additional work is charged on a cost-plus basis plus applicable taxes, subject to prior Company approval.
Material Changes and Agreements
On March 8, 2023, Amphastar entered into an Amendment to a Contract Research Agreement dated July 5, 2022, with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin").
- Scope of Work: Hanxin will perform scale-up manufacturing process development using Recombinant Human Insulin Research Cell Banks (RCBs).
- Intellectual Property: Amphastar retains ownership of all confidential and proprietary information, technology, and data produced during the scale-up manufacturing.
- Term: The Amendment remains in effect until July 5, 2025.
Related Party Transaction and Governance
The filing discloses that this is a related party transaction. Dr. Jack Zhang (CEO, President, Director) and Dr. Mary Luo (Chairman, COO, Director), along with certain family members, beneficially own a majority of the equity interest in Hanxin. The independent and disinterested members of the Audit Committee evaluated and approved the Amendment.
Investor Verification Checklist
- Verify the final cost of the Amendment against the $0.5 million cap in the upcoming Form 10-Q for the quarter ending March 31, 2023.
- Review the full text of the Amendment filed as an exhibit to the Form 10-Q for detailed rights and obligations.
- Monitor future filings for any "additional work" requests that may incur costs on a cost-plus basis.
- Confirm the status of the Recombinant Human Insulin Research Cell Banks (RCBs) development in subsequent operational updates.